Etuvetidigene Autotemcel: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Etuvetidigene Autotemcel. Educational only — not medical advice.
Labeled uses
WASKYRA® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.
Source: FDA labeling via NIH DailyMed (set 106880df…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.